A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Joseph P. Eder(Yale Cancer Center), Donald Küfe(Dana-Farber Cancer Institute), Philip W. Kantoff(Convergent Science (United States)), Jackelyn Y. Boyden, Dennis Panicali(Fox Chase Cancer Center), Philip M. Arlen(Dana-Farber Cancer Institute), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Linda Gritz, Gail P. Mazzara(Rogers (United States)), Guangxian Xu(Guangdong Medical College), Kwong-Yok Tsang(National Cancer Institute), Kristin Röper, Jeffrey Schlom(National Institutes of Health), Glenn J. Bubley(Sidney Kimmel Comprehensive Cancer Center)
PubMed
May 1, 2000
Cited by 296
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k